Navigation Links
Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study of Milnacipran for the Management of Fibromyalgia
Date:12/8/2008

NEW YORK and SAN DIEGO, Dec. 8, 2008 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX) and Cypress Bioscience, Inc. (Nasdaq: CYPB) today announced positive top-line results from a 1,025 patient, multicenter, double-blind, placebo-controlled phase III study of milnacipran for the management of fibromyalgia. These results, which confirm the findings from the two previous phase III trials, showed that milnacipran demonstrated a highly statistically significant difference to placebo in responder analyses based on a concurrent and clinically meaningful improvement in pain, patient global impression of change, and physical functioning. Comprehensive analyses of the study data will be completed in the coming weeks, and it is anticipated that further results will be presented during 2009.

(Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO )

Study Background

In this study, designated MLN-MD-03, patients with an established history of fibromyalgia were enrolled at 75 centers in North America and randomized to receive a daily dose of 100 mg of milnacipran (n=516) or placebo (n=509). The design of the double-blind study included a 4 to 6-week dose escalation phase, a 12-week stable-dose treatment phase, and a 2-week discontinuation phase. The primary efficacy endpoints were the proportion of subjects meeting criteria as composite responders based on one of two definitions. In the first co-primary analysis, a patient had to demonstrate simultaneous improvements on both their daily pain ratings (visual analog scale) and on an overall measure of how their fibromyalgia condition had been since the start of the stu
'/>"/>

SOURCE Forest Laboratories, Inc.; Cypress Bioscience, Inc.
Copyright©2008 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
2. Forest Laboratories, Inc. and Gedeon Richter Announce Results of Phase II-B Study for RGH-188 as a Treatment for Schizophrenia
3. Forest Laboratories, Inc. Announces Positive Results of LEXAPRO(R) Phase III Study in Adolescents With Major Depression
4. Microbia and Forest Laboratories Announce Preliminary Results of Linaclotide Phase 2b Studies
5. Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD
6. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
7. Forest Laboratories Announces Positive Results from Phase III Clinical Studies of Ceftaroline for the Treatment of Complicated Skin and Skin Structure Infections
8. Ironwood and Forest to Present Positive Data From Linaclotide Phase 2b IBS-C Study at ACG Annual Scientific Conference
9. Forest Laboratories, Inc. and Gedeon Richter Plc Announce Positive Phase II Results with the Investigational Antipsychotic Cariprazine in Patients with Acute Mania Associated with Bipolar I Disorder
10. Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
11. Roxane Laboratories, Inc. Updated Launch of Calcium Acetate Capsules, 667mg
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 21, 2013  Zacks.com announces the list of stocks ... Equity Research analysts discuss the latest news and events ... in the blog include Actavis, Inc.,s (NYSE: ACT ... (NYSE: TOT ), Petrobras (NYSE: PBR ) ... (Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO ) Get ...
(Date:5/21/2013)... , May 21, 2013  Cephasonics, ... platform, today announced the introduction of the ... complete network-based communications with all cQuest Ultrasound™ ... embedded-ultrasound technology, including this new capability, at ... Paulo, Brazil from May 21-24.  ...
(Date:5/21/2013)... May 21, 2013  Vasomedical, Inc. (OTC BB: VASO) (the ... manufacture and sale of medical devices and in the domestic ... Jun Ma , President and CEO of Vasomedical, ... Conference on Thursday, May 30, 2013 in New ... The Company,s presentation is scheduled to begin at ...
Breaking Medicine Technology:The Zacks Analyst Blog Highlights: Actavis, BP, Total, Petrobras and Devon Energy 2The Zacks Analyst Blog Highlights: Actavis, BP, Total, Petrobras and Devon Energy 3The Zacks Analyst Blog Highlights: Actavis, BP, Total, Petrobras and Devon Energy 4The Zacks Analyst Blog Highlights: Actavis, BP, Total, Petrobras and Devon Energy 5Cephasonics Unveils Next-Generation Wireless-Imaging Technology for cQuest Ultrasound Hardware Platforms 2Vasomedical, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 2
(Date:5/21/2013)... NY (PRWEB) May 21, 2013 Two-thirds ... or non-small cell lung cancer reported that they engage ... their medicine use, according to new findings from the ... by Kantar Health . The research will be ... ISPOR (International Society for Pharmacoeconomics and Outcomes Research) in ...
(Date:5/21/2013)... CA (PRWEB) May 21, 2013 ... was voted #1 for plastic surgery SEO services ... respondents were asked to name the “Best Plastic ... services say the outcome was predictable. Well-known in ... identified more by patients than any other selection ...
(Date:5/21/2013)... 2013 It’s nearly summer and millions of ... starting practice for summer or fall sports. In many ... activities can begin. , To help parents during this ... sports or camp physicals at just $29. ... a child’s medical history, perform a physical exam and complete ...
(Date:5/21/2013)... Nearly 40 Platinum Supplemental Insurance Sales Representatives and ... Cabos, Mexico, Feb. 23-March 1, 2013, to help renovate Casa ... facility serves meals and provides a social outlet for 45 ... Platinum Vice President, Mike Muench, says that the idea for ... “Platinum got its start selling long-term care insurance ,” ...
(Date:5/21/2013)... 2013 Access MediQuip, LLC , ... company, announced today that it has expanded its national ... nation's largest health benefits companies, with more than 36 ... 66 million individuals served through its subsidiaries. , WellPoint ... implant management program agreement back in 2008. Under the ...
Breaking Medicine News(10 mins):Health News:Two in Three Cancer Patients are Non-Adherent with Their Medications, According to Kantar Health Research 2Health News:Two in Three Cancer Patients are Non-Adherent with Their Medications, According to Kantar Health Research 3Health News:JD Media Surge's CosmeticSurgeonsOnline.com Voted #1 Source for Plastic Surgery SEO 2Health News:MedSpring Offers Camp and Sports Physicals For $29 2Health News:Platinum Supplemental Insurance Gives Back at Casa De Dia, Mexico 2Health News:Platinum Supplemental Insurance Gives Back at Casa De Dia, Mexico 3Health News:Access MediQuip and WellPoint Renew and Expand National Contract for Implantable Medical Devices 2Health News:Access MediQuip and WellPoint Renew and Expand National Contract for Implantable Medical Devices 3
... results from a large-scale study of key antimalarial medicines ... percentage of medicines circulating on national markets are of ... of drug-resistant strains of Plasmodium falciparum , the ... by the Promoting the Quality of Medicines (PQM) Program, ...
... of advanced breast cancer diagnosis among black women remained ... women between 1992 and 2004, according to new findings ... addition, the disparity in the incidence of advance colorectal ... fell among whites but increased slightly among blacks. , ...
... ... significant achievement and differentiates Hallmark Insights from its peers in the incentive services ... (PRWEB) ... that it has successfully completed a Statement on Auditing Standards (SAS) 70 Type II ...
... Small study reports improvement in thinking skills, , ... drug may improve thinking, learning and memory skills ... disorder, new research says. , Huntington,s affects movement, ... disease usually die within 10 to 30 years ...
... brass support improved school nutrition to cut obesity, ensure qualified recruits ... Johnnie E. Wilson , U.S. Army (Ret.), and Lieutenant General ... preventing child obesity is a matter of national security, noting that ... are unable to enlist in the armed services. The generals, comments ...
... , Feb. 9 The National ... join the Commission on Cancer (CoC), a multidisciplinary organization administered ... morbidity and mortality of cancer through education, standards setting, and ... has invited NCCS, a key patient advocacy organization, to join ...
Cached Medicine News:Health News:One-third of antimalarial medicines sampled in 3 African nations found to be substandard 2Health News:One-third of antimalarial medicines sampled in 3 African nations found to be substandard 3Health News:Racial disparities persist in the diagnosis of advanced breast cancer and colon cancer in the U.S. 2Health News:Racial disparities persist in the diagnosis of advanced breast cancer and colon cancer in the U.S. 3Health News:Racial disparities persist in the diagnosis of advanced breast cancer and colon cancer in the U.S. 4Health News:Hallmark Insights Completes SAS 70 Type II Audit 2Health News:Drug May Ease Cognitive Effects of Huntington's 2Health News:Retired Military Brass Support First Lady's Call to Reduce Child Obesity, Improve Nutrition 2Health News:The National Coalition for Cancer Survivorship Joins the Commission on Cancer 2
... new Propaq LT is the perfect monitor ... basic parameters of continuous vital signs monitors ... making it perfect for just about any ... Light enough to clip on an IV ...
Exxcel Soft ePTFE vascular graft, designed for exceptional kink resistance and crush resistance, maintains a Soft touch for easier handling during peripheral vascular bypass procedures and vascular a...
... is used for the processing ... independent medical billers. It is ... generate and transmit claims to ... commercial insurance carriers. It utilizes ...
BillingPro...
Medicine Products: